Compare FOXX & PLUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FOXX | PLUR |
|---|---|---|
| Founded | 2017 | 2001 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.0M | 33.9M |
| IPO Year | N/A | 2001 |
| Metric | FOXX | PLUR |
|---|---|---|
| Price | $4.00 | $3.34 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | ★ 8.5K | 6.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 10.78 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,336,000.00 |
| Revenue This Year | N/A | $97.38 |
| Revenue Next Year | N/A | $293.97 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 309.82 |
| 52 Week Low | $1.71 | $2.82 |
| 52 Week High | $8.70 | $7.13 |
| Indicator | FOXX | PLUR |
|---|---|---|
| Relative Strength Index (RSI) | 39.60 | 45.91 |
| Support Level | $3.80 | $3.19 |
| Resistance Level | $4.80 | $3.50 |
| Average True Range (ATR) | 0.40 | 0.15 |
| MACD | -0.12 | -0.04 |
| Stochastic Oscillator | 5.03 | 23.20 |
Foxx Development Holdings Inc is a consumer electronics and integrated Internet-of-Things (IoT) solution company catering to both retail and institutional clients. With robust research and development capabilities and a strategic commitment to cultivating long-term partnerships with mobile network operators, distributors, and suppliers. Its products include tablets, smartphones, wearables, and other high-quality communication terminals. The company's current revenue stream is derived from the sales of tablets and smartphones.
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.